Kornimate/medical-research-clean huggingface dataset:
comparison of the efficacy of ultrasound guided vs non-guided suprascapular nerve block treatment in stroke patients

Conditions: Hemiplegia; Stroke

Summary: the aim of this study is to compare the effectiveness of ultrasound-guided and non-guided suprascapular nerve block in the treatment of patients with hemiplegic shoulder pain, which is one of the most common post-stroke complications.

hemiplegic shoulder pain is a general term used to describe shoulder pain that occurs after a stroke. it is one of the complications that significantly affects the rehabilitation of patients.the suprascapular nerve takes up 70% of the sensation of the shoulder joint. for this reason, suprascapular nerve block treatment is applied in the treatment of hemiplegic shoulder pain.in patients with hemiplegic shoulder pain, suprascapular nerve block therapy can be performed under ultrasound guidance or using anatomical landmarks. however, there is no study in the literature comparing the effectiveness of ultrasound-guided and unguided suprascapular nerve block in the treatment of hemiplegic shoulder pain patients with hemiplegic shoulder pain among the patients who received routine conservative rehabilitation treatment in the physical therapy and rehabilitation clinic with the diagnosis of post-stroke hemiplegia will be included in the study. hemiplegic patients aged 25-75 years, with shoulder pain lasting for 3 months and with a visual analogue scale (vas) value \> 3 during passive shoulder joint movement will be included in the study. exclusion criteria from the study will be determined as mini mental test score \< 24, uncontrolled diabetes, coagulopathy, botulinum toxin administration in the last six months, any injection from the shoulder region in the last six months, and hypersensitivity to injection agents. it will be organized as a prospective randomized study. it is planned to include 50 patients in the study. patients will be randomized into two groups in equal numbers, stratified by age and sex. patients in group 1 will be applied with ultrasound-guided suprascapular nerve block. patients in group 2 will be applied with suprascapular nerve block using defined anatomical points without ultrasound guidance. initially, demographic data, medical history, stroke etiology, duration of stroke, body mass index, hemiplegic side information of the patients will be obtained. patients in both groups will be evaluated in terms of shoulder joint range of motion, visual analogue scale, brunnstrom stages of stroke recovery, barthel index, modified ashworth scale, the beck depression inventory before the treatment, at the 1st week, 1st month and 3rd month after the injection.

Eligibility criteria:
inclusion criteria: * having hemiplegic shoulder pain for 3 months * visual analogue scale score \> 3 during passive shoulder joint movement on the hemiplegic side exclusion criteria: * mini mental test score \<24 * patients with uncontrolled diabetes, coagulopathy * botulinum toxin administration in the past six months, * any injection in the shoulder region in the last six months * having hypersensitivity to injection agents
the effect of compression stockings on edema and discomfort during short haul flights

Conditions: Edema Leg

Summary: compression stockings have beneficial effects on the development of venous thromboembolic complications and oedema during long- haul flights. a randomized controlled trial investigating the effect of compression stockings during short-haul flights with a duration less than fur ours is lacking. deep vein thrombosis is very rare on flights shorter than four hours, but compression stocking could have beneficial effects on other outcomes. the aim of this study is to assess if compression stockings used during a 3-3.5-hour flight will decrease leg edema and discomfort.

all participants will be adults who will undergo a 3-3.5 hours flight. participants have received oral and written information about the trial. all compression stockings have a class two compression level (corresponding to 23-32 mmhg compression). participants will be randomized to wear a compression stocking on one leg, while the other side acts as control. within an hour preflight, the patient will measure ankle and calf circumference at marked circumferential areas on the leg and answer questionnaires regarding leg pain and subjective discomfort, whereafter the stocking will be put on, on the randomized side. within one hour after the flight the stocking will be removed and patients will once again measure the ankle and calf circumference at the marked circumference and fill out the questionnaire. sample size: mean difference in ankle circumference set to -0.19 cm. standard deviation of the mean difference set to 0.3, 5% alfa and 80% power. sample size with a paired design = at least 18 participants. however, for practical reasons we will include up to approximately 50 adults in the trial. withdrawal and dropout criteria: all participants can withdraw their consent at any point during the trial, without the need for explaining any reasons for withdrawal. since compression stockings do not cause side effects, except for patients with severe arterial insufficiency in the legs, we do not expect the trial to be stopped due to complications. all withdrawals will be accounted for in the scientific publication.

Eligibility criteria:
inclusion criteria: * adult participants ≥ 18 years of both sexes. otherwise no restriction, since each participant acts as their own control. exclusion criteria: * any condition requiring compression stockings during short-haul flights. severe arterial insufficiency in the lower extremities.
efficacy of add-on plasma exchange as an adjunctive strategy against septic shock

Conditions: Septic Shock

Summary: randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.

sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection; in septic shock profound circulatory, cellular and metabolic abnormalities are associated with an even higher mortality. sepsis is a major healthcare problem, affecting millions of individuals around the world each year. its incidence appears to be rising, and the mortality caused by septic shock in germany in 2015 remains extraordinarily high (58.8%). it is well known - from the pathophysiological point of view - that these patients do not die from their infection per se but rather from multiple organ failure caused by their own overwhelming host response. this fact is so fundamental that it has been implemented as a key part of the 2016 sepsis definition (sepsis-3). despite tremendous efforts during the last decades, innovative approaches targeting this fundamental hallmark of the disease, thereby reducing organ dysfunction, are lacking. undoubtedly, there is an unmet need to expand the current standard of care for these patients by a more specific intervention. the investigators hypothesize that early therapeutic plasma exchange (tpe) in the most severely ill individuals will dampen the injurious maladaptive host response by removing injurious mediators thereby limiting organ dysfunction. the potential impact of this trial is of immense clinical relevance as it evaluates a promising adjunctive treatment option for a patient cohort suffering from an extraordinary high mortality. a positive trial result could truly change the current standard of care (soc) - that is mostly supportive - of septic shock patients. of note, there is neither a patent nor a direct commercial interest in such a trial.

Eligibility criteria:
inclusion criteria: * new onset of septic shock (\< 24 hrs), (sepsis-3 definition) * norepinephrine (ne) dose ≥ 0.4 μg/kg/min ≥ 30 min or ne ≥ 0.3 μg/kg/min + vasopressin (any dose) * established vascular access suitable for plasma exchange independent of study inclusion (due to established indication of rrt, expected need for rrt within the next 48 hours or other medical reasons as assessed by treating physician team) exclusion criteria: * age \ 80 years * urogenital focus of infection * pregnancy * heparin-induced thrombocytopenia * known reaction against fresh frozen plasma (ffp)

Keywords: septic shock sepsis multi-organ failure extracorporeal therapy plasmapheresis
a trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of liraglutide in obese children aged 7 to 11 years

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in the united states of america. the aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of liraglutide in obese children aged 7 to 11 years


Eligibility criteria:
inclusion criteria: * male or female subjects aged 7-11 years (both inclusive) at the time of signing informed consent * tanner stage 1 (including subjects with premature adrenarche) at the time of signing informed consent * bmi (body mass index) corresponding to above or equal to 30 kg/m\^2 for adults by international cut-off points (cole et al 2000)1 and bmi below or equal to 45 kg/m\^2 as well as bmi above or equal to 95th percentile for age and gender exclusion criteria: * subjects with secondary causes of childhood obesity (i.e., hypothalamic, genetic or endocrine causes) * subjects with confirmed bulimia nervosa disorder * diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus as defined by glycosylated haemoglobin (hba1c) above or equal to 6.5 % * history of pancreatitis (acute or chronic) * presence of severe co-morbidities as judged by the investigator * family or personal history of multiple endocrine neoplasia type 2 (men2) or medullary thyroid carcinoma (mtc) * history of major depressive disorder within 2 years before randomisation
aerobic exercise in boys with duchenne muscular dystrophy (dmd)

Conditions: Duchenne Muscular Dystrophy

Summary: this research study wants to learn more about duchenne muscular dystrophy (dmd) and exercise. today it is unknown how exercising impacts boys with dmd. the investigators believe that increasing activity and aerobic exercise may help with heart, lung, and muscle function. the investigators are hoping to compare physical strength and blood samples of boys with dmd to see if there are any differences between kids who exercised more as a child versus those who didn't.

recently, the american academy of neurology released new guidelines for children with duchenne muscular dystrophy (dmd) with an updated recommendation to include moderate aerobic exercise. historically, children with dmd were advised to not exercise as it was thought to accelerate muscle loss. today, there is new data suggesting that moderate aerobic exercise that does not strain muscle may be beneficial and improve a child's quality of life with regard to heart disease, fatigue, and other factors of overall health. although it is expected that children who exercise will experience health benefits, there is no scientific evidence indicating a positive or negative effect in a dmd population. this study is trying to understand the role of aerobic exercise in boys with dmd and how it may impact heart, muscle, and lung function using newly identified biomarkers. the goal is to correlate increased aerobic exercise with improved functional outcomes and changes in biomarkers. the data collected from this study will allow future development and implementation of an innovative and disease-specific home aerobic exercise program that in the future will be recommended to families of children with dmd.

Eligibility criteria:
inclusion criteria: * ages 2-17 years old with a confirmed diagnosis of dmd. has an appointment in mda clinic at the ann \& robert h. lurie children's hospital of chicago. exclusion criteria: * is less than two years old and does not have a confirmed diagnosis of dmd.

Keywords: exercise aerobic exercise
multicenter study of risk-adapted treatment for t-lineage all of young adults (18-59 years old)

Conditions: T-cell Adult Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to evaluate the efficacy of nelarabine-based consolidation and maintenance therapy in term of relapse-free survival (rfs) in high-risk (hr) patients.


Eligibility criteria:
inclusion criteria: 1. whose blood and bone marrow explorations have been completed before the steroids prephase 2. aged 18-59 years old with a not previously treated (including it injection) t-all newly-diagnosed according to the who 2008 definition with \> 20% bone marrow blasts 3. with eastern cooperative oncology group (ecog) performance status \< 3 4. with or without central nervous system (cns) involvement or testis 5. without other evolving cancer (except basal cell carcinoma of the skin and "in situ" carcinoma of the cervix) or its chemo or radio-therapy treatment finished at least since 6 months 6. having signed a written informed consent 7. with efficient contraception for women of childbearing age (excluding estrogens and iud) 8. having received or being receiving steroid prephase 9. with health insurance coverage exclusion criteria: 1. with lymphoblastic lymphoma and bone marrow blasts \< 20%, burkitt-type all or with antecedents of chronic myeloid leukemia (cml) or other myeloproliferative neoplasm 2. with contra-indication to anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the all: * aspartate transaminase (ast) and/or alanine transaminase (alt) \> 5 x upper limit of normal range (uln) * total bilirubin ≥ 2.5 x upper limit of normal range (uln) * creatinine \> 1.5 x upper limit of normal range (uln) or creatinine clearance \<50 ml/mn 3. myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy (nyha grade iii or iv), left ejection ventricle fraction (levf) \< 50% and/or rf \< 30%, 4. active severe infection or known seropositivity for hiv or human t cell leukemia/lymphoma virus type 1 (htlv-1) or active hepatitis b or c 5. other active malignancy 6. pregnant (beta-human chorionic gonadotropin (hcg) positive) or nursing woman 7. women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least three months thereafter. patients not willing to ensure not to beget a child during participation in the study and at least three months thereafter 8. treated with any other investigational agent or participation in another trial within 30 days prior to entering this study 9. not able to bear with the procedures or the frequency of visits planned in the trial 10. unable to consent, under tutelage or curators, or judiciary safeguard
evaluate the efficacy of herbal medicine (shaoyao gancao decoction jiawei) in sleep-related leg cramps

Conditions: Sleep-related Leg Cramps

Summary: sleep-related leg cramps (srlcs) are a sleep-related movement disorder whereby painful contractions of the calf or foot muscles arise at sleep onset and during sleep and awaken the patient, interrupting sleep. application of oral administration with chinese herbal medicine can enhance the effectiveness and efficacy in treatment of srlcs.this study will using shaoyao gancao prescription jiawei by adding pueraria montana, salvia miltiorrhiza, into shaoyao gancao. the study aims to evaluate the effectiveness of a shaoyao gancao prescription jiawei in relieving leg cramps.

the study will be conducted in yan oi tong mrs shirley w k siu medical centre. all participants diagnosed with sleep-related leg cramp will be screened for eligibility criteria from the general public or referred patients via daily outpatient services. this will be a prospective trial in patients with sleep-related leg cramps (srlcs). 30 subjects will be recruited from yan oi tong mrs shirley w k siu medical centre. the medication will be taken twice daily for 28 consecutive days. each prescription will consist of 4 herbal granules. study follow up will be offered every 7 days till 56th day after enrolment. daily leg cramps log will be filled in by each individual everyday from day 0 to day 56.

Eligibility criteria:
inclusion criteria: 1. aged 60-80 2. complain of muscular spasm and contracture of a limb with difficulty in relaxation and movement during night time, caused by wind-cold dampness chiefly involving the sinews 3. srlcs occur at least once in the past 7 days or twice in the past 14 days 4. visual analogue scale (vas) for leg cramp ≥ 5 (0-10) at the last attack 5. both gender but menopause or sterilization for female subjects 6. able to fill up the vas for leg cramp 7. written informed consent obtained exclusion criteria: 1. known mental disorder 2. known serious organic disease including severe coronary function impairment, post-stroke depression and dementia, and auto-immune diseases 3. known history of renal or liver function impairment; 4. patients whose blood tests show exclusion criteria 5. currently taking anticoagulant or antiplatelet 6. any contraindications for taking herb confirmed by investigator -
vitamin d supplementation in acne

Conditions: Acne Vulgaris

Summary: the goal of this clinical trial is to compare in acne vulgaris patients. the main question it aims to answer is: • to assess the therapeutic benefit of vitamin d supplement in acne vulgaris treatment, following a 2-month treatment regimen that includes vitamin d supplementation compared to conventional (systemic azithromycin and topical retinoid) treatment alone. participants will receive vitamin d supplements in addition to capsule azithromycin and topical retinoid. researchers will compare groups to determine efficacy of vitamin d supplements in the treatment of acne vulgaris.


Eligibility criteria:
inclusion criteria: * individuals aged between 13 and 40 years with diagnoses of acne vulgaris are included. exclusion criteria: * individuals currently undergoing treatment for polycystic ovary syndrome (pcos) * those with obesity * individuals employing vitamin supplementation * those under the influence of topical or systemic steroids and acne treatment in the last 2 months.

Keywords: acnevulgaris vitamin d
evaluation of the relationship between ond and onsd measured by tos with clinical, radiological, and electrophysiological parameters in ms patients

Conditions: Multiple Sclerosis

Summary: the primary aim of this study is to evaluate the reliability of optic nerve diameter (ond) and optic nerve sheath diameter (onsd) measurements made with transorbital sonography (tos) and magnetic resonance imaging (mri) in patient groups that may progress with subclinical optic atrophy over time, such as those with multiple sclerosis (ms). the secondary aims of this study are to compare the relationship of tos with visual evoked potentials (vep) and optical coherence tomography (oct) parameters used in the assessment of the afferent visual pathway in ms and its clinical subtypes and to evaluate the potential of tos as a diagnostic and monitoring tool for detecting optic nerve atrophy, subclinical axonal loss, and clinical disability in ms.

the study included 102 patients with ms-81 with relapsing-remitting ms (rrms), 19 with secondary progressive ms (spms), and 2 with primary progressive ms (ppms)-as well as 34 healthy controls, all selected according to the inclusion and exclusion criteria. demographic data for all participants, and clinical characteristics of the ms patient group, were recorded. expanded disability status scale (edss) measurements were performed for the patients. then, tos, orbital mri, vep and oct examinations were applied to the individuals in the patient group on the same day for each eye. measurements recorded included ond and onsd by tos and mri, p100 latency and amplitude by vep, and peripapillary retinal nerve fiber layer (prnfl) thickness by oct. in the healthy control group, ond and onsd were measured using only transorbital tos to establish normal measurement ranges.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * having been diagnosed with multiple sclerosis * undergoing disease-modifying therapy (dmt) for more than 6 months * edss score ≤ 7 exclusion criteria: * patients whose multiple sclerosis diagnosis is uncertain * having ocular pathology that may affect optic nerve measurements (e.g., glaucoma, high myopia, history of ocular surgery) * having major systemic diseases that may affect optic nerve measurements (e.g., diabetes mellitus, hypertension) * edss score \> 7 * having experienced a clinical relapse or optic neuritis within the last 6 months.

Keywords: multiple sclerosis transorbital sonography optic nerve sheath diameter optic nerve diameter magnetic resonance imaging visual evoked potentials optical coherence tomography
a randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of dilatrend sr 64mg capsule after oral administration in healthy male volunteers

Conditions: Chronic Stable Angina

Summary: a randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of dilatrend sr 64mg capsule after oral administration in healthy male volunteers.


Eligibility criteria:
inclusion criteria: * between 20 aged and 50 aged in healthy adults * weight more than 55kg, ibw 20% within the range * agreement with written informed consent exclusion criteria: * subject has hypersensitivity reaction or clinically significant history about investigational drug * clinically significant cardiovascular system, respiratory system, liver, renal, endocrine system, gastrointestinal system, central nervous system, blood tumor, mental disease, skin disease and so on * inadequate result of laboratory test * ast(sgot) or alt(sgpt) \> 1.5 x upper limit of normal range * continued to be taking caffeine (caffeine \> 5 cup/day), drinking(alcohol \> 210 g/day) or during clinical trials can not be drunk or severe heavy smoker (cigarette \> 10 cigarettes per day) * creatinine clearance \< 80ml/min * subject with known for history(such as gastrointestinal disease or operation) with affect the absorption of drug * subject takes an abnormal meal which affect the adme of drug * previously participated in other trial within 90 days * previously make whole blood donation within 60 days or component blood donation within 30 days * subject with positive reaction for reason of laboratory test result * an impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result

Keywords: food effect pharmacokinetics healthy male volunteers